INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN3m ago
Public company

COLLCOLLEGIUM PHARMACEUTICAL, INC

CIK 0001267565

EDGAR filingsOpen in network
Disclosed transactions19
Buys / sells0 / 7
Max Insider Score33
Connections10with evidence

COLL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GM
Glancy Donovan MichaelDirector
COLLCOLLEGIUM PHARMACEUTICAL, INC
Grant or award
A—
17.5K sh
May 14, 2026May 18, 2026
traded May 14, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORALDA Q3Y 2026 third quarter · issues not listed · Nov 3, 2026
  • ← Lobbied forevidence
    NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLCLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
25
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Tax withholding
F
$316K
8,840 sh
Mar 17, 2026
Apr 3, 2026
traded Mar 17, 2026
+17d
SEC FORM 4

Evidence

11
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$488K
14.0K sh
Mar 18, 2026Mar 20, 2026
traded Mar 18, 2026
+2dSEC FORM 4

Evidence

12
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$228K
6,224 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

13
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Grant or award
A—
9,005 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

12
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Tax withholding
F$130K
2,781 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

15
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Tax withholding
F$555K
11.9K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

13
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Grant or award
A—
26.4K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

22
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Tax withholding
F$1.25M
26.7K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

13
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Grant or award
A—
32.7K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

17
DD
Dieter DavidEVP & General Counsel
COLLCOLLEGIUM PHARMACEUTICAL, INC
Grant or award
A—
22.2K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC FORM 4

Evidence

9
DS
Dreyer ScottEVP & Chief Commercial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Option exercise · 10b5-1 plan
M$280K
17.6K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

0
DS
Dreyer ScottEVP & Chief Commercial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Option exercise · 10b5-1 plan
M—
17.6K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

20
DS
Dreyer ScottEVP & Chief Commercial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$315K
6,475 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

20
DS
Dreyer ScottEVP & Chief Commercial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$533K
11.1K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

33
BJ
Balice-Gordon Rita J.Director
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale
SELL$172K
3,650 sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

19
KV
Karnani VikramDirector, President and CEO
COLLCOLLEGIUM PHARMACEUTICAL, INC
Tax withholding
F$425K
8,983 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

8
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$201K
4,858 sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

18
TC
Tupper ColleenEVP & Chief Financial Officer
COLLCOLLEGIUM PHARMACEUTICAL, INC
Open-market sale · 10b5-1 plan
SELL$1.02M
25.1K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

JEFFREY J. KIMBELL & ASSOCIATES, INC.
LDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Glancy Donovan MichaelDirector · May 18, 2026
  • ← Insider ofevidence
    Dieter DavidEVP & General Counsel · Feb 12, 2026
  • ← Insider ofevidence
    Dreyer ScottEVP & Chief Commercial Officer · Dec 10, 2025
  • ← Insider ofevidence
    Balice-Gordon Rita J.Director · Dec 9, 2025
  • ← Insider ofevidence
    Karnani VikramDirector, President and CEO · Nov 14, 2025
  • ← Insider ofevidence
    Tupper ColleenEVP & Chief Financial Officer · Nov 7, 2025

    • Lobbying

    $190K reported · de-duplicated
    2026 Q3 $60K via firms2026 Q2 $40K via firms2026 Q1 $90K via firms
    • SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA$60K2026 Q3 · posted Nov 3, 2026 ·
    • SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA—2026 Q2 · posted Aug 26, 2026 ·
    • NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC$20K2026 Q1 · posted Aug 26, 2026 · Health issues
    • SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA$60K2026 Q1 · posted Aug 26, 2026 ·
    • NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC—2026 Q1 · posted Aug 26, 2026 · Health issues
    • JEFFREY J. KIMBELL & ASSOCIATES, INC.$10K2026 Q2 · posted Aug 26, 2026 · Health issues
    • JEFFREY J. KIMBELL & ASSOCIATES, INC.$10K2026 Q1 · posted Aug 26, 2026 · Health issues
    • SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORMERLY KNOWN AS SONORA—2026 Q1 · posted Aug 26, 2026 · Pharmacy
    • NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC$30K2026 Q2 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.